Echo Therapeutics (ECTE) Posts Wider than Expected Q2 Loss of 8c/Share
Tweet
Share
E-mailGet Alerts ECTE Hot Sheet
Price: $0.00 --0%
Financial Fact:
Research and development: 588.55K
Today's EPS Names:
YRD, CAG, CALM, More
Financial Fact:
Research and development: 588.55K
Today's EPS Names:
YRD, CAG, CALM, More
Join SI Premium – FREE
Echo Therapeutics (NASDAQ: ECTE) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.9 thousand versus the consensus estimate of $190 thousand.
For earnings history and earnings-related data on Echo Therapeutics (ECTE) click here.
For earnings history and earnings-related data on Echo Therapeutics (ECTE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Halozyme adds Jim Daly to its board of directors
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
